Basilea Pharmaceutica AG

Swiss Stock Exchange:BSLN.SW

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 736.21 M

Share Price

USD 59.54

Avg Daily Volume

42,074

Change (1 day)

-0.71%

Change (1 year)

34.70%

Change (YTD)

30.23%

Basilea Pharmaceutica AG Free Cash Flow Yield on June 27, 2025: 10.87%

Basilea Pharmaceutica AG Free Cash Flow Yield is 10.87% on June 27, 2025, a 268.46% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Basilea Pharmaceutica AG 52-week low Free Cash Flow Yield is 14.16% on June 27, 2025, which is 30.31% above the current Free Cash Flow Yield.
Basilea Pharmaceutica AG 52-week low Free Cash Flow Yield is 2.30% on June 27, 2025, which is -78.83% below the current Free Cash Flow Yield.
Basilea Pharmaceutica AG average Free Cash Flow Yield for the last 52 weeks is 5.29%.

Daily

From:

To:

Zoom:

Key data

Date	Free Cash Flow Yield	Dividend Yield	Market Capitalization	Share Price

Swiss Stock Exchange: BSLN.SW

Basilea Pharmaceutica AG

CEO	Mr. David Veitch
IPO Date	March 25, 2004
Location	Switzerland
Headquarters	Grenzacherstrasse 487
Employees	164
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.